Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: Does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 3, 2012, Pages 611-616

  Bashir, Mustafa R ^a   Husarik, Daniela B ^a,b   Ziemlewicz, Tim J ^a   Gupta, Rajan T ^a   Boll, Daniel T ^a   Merkle, Elmar M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

flip angle; gadoxetate; Gd EOB DTPA; hepatobiliary; hepatocyte phase

Indexed keywords

ECHO CONTRAST MEDIUM; ECHOVIST; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMMON BILE DUCT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; LIVER; LIVER CELL; LIVER INJURY; LIVER MAGNETIC RESONANCE IMAGING; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STUDENT T TEST;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEPATOCYTES; HUMANS; IMAGE ENHANCEMENT; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84857089420     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22850     Document Type: Article

References (30)

1. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
2. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
3. Lauenstein TC, Salman K, Morreira R, et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol 2007; 189: 663-670. (Pubitemid 47328550)
4. Saini S, Ralls PW, Balfe DM, et al. Liver lesion characterization. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 Suppl: 193-199.
5. Miller JC, Hahn PF, Chung RT, Thrall JH, Lee SI,. Screening for hepatocellular carcinoma in cirrhotic patients. J Am Coll Radiol 2008; 5: 1012-1014.
6. Takuma Y, Nouso K,. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16: 1436-1441.
7. Taouli B, Ehman RL, Reeder SB,. Advanced MRI methods for assessment of chronic liver disease. AJR Am J Roentgenol 2009; 193: 14-27.
8. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 2009; 19: 2623-2629.
9. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001; 221: 731-739. (Pubitemid 33101765)
10. Kim YK, Lee YH, Kwak HS, Kim CS, Han YM,. Detection of liver metastases: gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran- enhanced MR imaging. Eur J Radiol 2010; 73: 131-136.
11. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009; 193: 1053-1060.
12. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006; 30: 345-354. (Pubitemid 43922248)
13. Kim SH, Lee J, Kim MJ, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009; 192: 1675-1681.
14. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 151-158.
15. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010; 45: 96-103.
16. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
17. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
18. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-833.
19. Nagle S, Busse, RF, et al. High-resolution free-breathing 3D T1 weighted hepatobiliary imaging optimized for Gd-EOB-DTPA. In: Proc 17th Annual Meeting ISMRM, Honolulu; 2009: 2076.
20. Bashir MR, Merkle EM,. Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol 2011; 21: 291-294.
21. Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med 2010; 51: 692-699.
22. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010; 45: 133-141.
23. Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L,. Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009; 19 (Suppl 5): S975-989.
24. Goshima S, Kanematsu M, Watanabe H, et al. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas. Eur J Radiol 2011; 79: e108-112.
25. Okada M, Imai Y, Kim T, et al. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2010; 32: 903-913.
26. Gupta RT, Brady CM, Lotz J, Boll DT, Merkle EM,. Dynamic MR imaging of the biliary system using hepatocyte-specific contrast agents. AJR Am J Roentgenol 2010; 195: 405-413.
27. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging-correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-826.
28. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364.
29. Nilsson H, Nordell A, Vargas R, Douglas L, Jonas E, Blomqvist L,. Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 2009; 29: 1323-1331.
30. Dietrich O, Raya JG, Reeder SB, Reiser MF, Schoenberg SO,. Measurement of signal-to-noise ratios in MR images: influence of multichannel coils, parallel imaging, and reconstruction filters. J Magn Reson Imaging 2007; 26: 375-385. (Pubitemid 47257737)